Ascendis Pharma A/S

ASND· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$243.45-0.19%

2026-08-03

Financials

Valuation Metrics

Ascendis Pharma A/S's Market Cap is $15.04B. At end of 2025 it was $9.49B. Ranked #727 of 3,112 in US market (top 23%), #225 of 1,445 on NASDAQ (top 16%), #34 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 13%) by Market Cap.

Investment Metrics(as of 2026-08-03)

Metric	Value	Rank
Size
Market Cap	$15.04B	US#727/3,112 Sec#34/269
Revenue	$984M	US#1,953/3,112 Sec#54/269
Net Income	$574M	US#744/3,112 Sec#28/269
Total Assets	$2.36B	US#1,964/3,112 Sec#50/269
Net Assets	$574M	US#2,153/3,112 Sec#100/269
Value
P/E	26.19x	US#1,323/3,112 Sec#46/269
P/B	26.21x	US#2,862/3,112 Sec#241/269
P/S	15.29x	US#2,761/3,112 Sec#139/269
EV/EBITDA	1099.55x	US#2,503/3,112 Sec#92/269
FCF Yield	0.32%	US#2,214/3,112 Sec#82/269
Profitability
ROE	100.10%	US#31/3,112 Sec#3/269
ROA	24.38%	US#47/3,112 Sec#11/269
Op. Margin	-0.80%	US#2,448/3,112 Sec#89/269
Revenue Growth	148.29%	US#95/3,112 Sec#27/269
Financial Health
Debt Ratio	310.53%	US#2,149/3,112 Sec#222/269
Total Debt	$1.05B	US#1,452/3,112 Sec#42/269
FCF	$48M	US#1,945/3,112 Sec#70/269
Cash	$674M	US#884/3,112 Sec#40/269
Current Ratio	1.00x	US#2,285/3,112 Sec#261/269
Net Debt/EBITDA	27.15x	US#2,488/3,112 Sec#93/269
Performance
1Y Return	39.53%	US#1,139/3,112 Sec#139/269
1M Return	-11.31%	US#2,667/3,112 Sec#178/269
From 52W High	-13.72%	US#1,332/3,112 Sec#79/269
1Y MDD	-17.62%	US#495/3,112 Sec#16/269
Trading
Volume	519,504 shares	US#2,042/3,112 Sec#198/269
Trading Value	$126M	US#762/3,112 Sec#44/269
Per Share
EPS	$-4.01	US—/3,112 Sec—/269